IPP Bureau
Briefs: Lupin and Aurobindo Pharma
By IPP Bureau - May 13, 2024
Lupin updates on shipment of Mirabegron ER Tablets
Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr
By IPP Bureau - May 12, 2024
Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024
Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr
By IPP Bureau - May 11, 2024
The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024
Dr. Lal PathLabs posts Q4 FY24 consolidated PAT at Rs. 84.5 Cr
By IPP Bureau - May 11, 2024
The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024
Hester Biosciences posts Q4 FY24 consolidated profit increases to Rs. 4.95 Cr
By IPP Bureau - May 11, 2024
The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024
OMRON Healthcare India and AliveCor partner to improve heart healthcare in India
By IPP Bureau - May 11, 2024
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Strides receives USFDA approval for Sevelamer Carbonate Tablets
By IPP Bureau - May 11, 2024
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Ami Organics posts Q4 FY24 consolidated profit at Rs. 25.14 Cr
By IPP Bureau - May 11, 2024
Ami Organics has reported total income of Rs. 226.30 crores during the period ended March 31, 2024
Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr
By IPP Bureau - May 11, 2024
Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024
Neuland Laboratories posts Q4 FY24 consolidated PAT at Rs. 67.56 Cr
By IPP Bureau - May 11, 2024
Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024
Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
By IPP Bureau - May 10, 2024
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Abbott India posts Q4 FY24 PAT at Rs. 287.06 Cr
By IPP Bureau - May 10, 2024
The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024
Medico Remedies posts Q4 FY24 PAT at Rs. 3.09 Cr
By IPP Bureau - May 10, 2024
The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024
Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr
By IPP Bureau - May 10, 2024
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
Cipla receives 1 observation from USFDA for Kurkumbh facility
By IPP Bureau - May 10, 2024
The company is committed to address this observation comprehensively within stipulated time
